A study published in *Nature* (2014) demonstrates that the monoclonal antibody cocktail ZMapp™ can effectively treat advanced Ebola virus disease in nonhuman primates. When administered up to 5 days after infection, ZMapp™ rescued 100% of rhesus macaques, reversing severe symptoms such as high fever, viremia, and blood abnormalities. The cocktail, optimized from previous antibody combinations, showed cross-reactivity with the Guinean variant of Ebola. Results indicate that ZMapp™ is more effective than previous treatments, warranting further clinical development. The study highlights the potential of ZMapp™ as a promising therapeutic option for Ebola virus disease, particularly in outbreak scenarios. The findings support the use of monoclonal antibodies in treating Ebola, emphasizing their role in combating the virus. The study also notes the importance of continued research and development to improve therapeutic options for Ebola patients.A study published in *Nature* (2014) demonstrates that the monoclonal antibody cocktail ZMapp™ can effectively treat advanced Ebola virus disease in nonhuman primates. When administered up to 5 days after infection, ZMapp™ rescued 100% of rhesus macaques, reversing severe symptoms such as high fever, viremia, and blood abnormalities. The cocktail, optimized from previous antibody combinations, showed cross-reactivity with the Guinean variant of Ebola. Results indicate that ZMapp™ is more effective than previous treatments, warranting further clinical development. The study highlights the potential of ZMapp™ as a promising therapeutic option for Ebola virus disease, particularly in outbreak scenarios. The findings support the use of monoclonal antibodies in treating Ebola, emphasizing their role in combating the virus. The study also notes the importance of continued research and development to improve therapeutic options for Ebola patients.